Ariceum Therapeutics
Jessica Klaver Preston possesses extensive experience in clinical operations and project management within the pharmaceutical industry. Jessica has held several key positions, including Director of Clinical Operations and Site Engagement at Ariceum Therapeutics, Associate Director of Clinical Operations and Site Engagement Project Lead at BeiGene, and Senior Director and Head of Clinical Operations at Genor BioPharma Co., Ltd. Additionally, Jessica has worked as a freelance pharmaceutical consultant and advisor and served as Associate Director of Project Management Country Operations at Alexion Pharmaceuticals, Inc. Educational credentials include studies at British Columbia Institute of Technology and Simon Fraser University.
This person is not in any offices
Ariceum Therapeutics
1 followers
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.